The Basque bio-pharmaceutical company Histocell and the Cardiva Group, both members of the Basque Health Cluster, have joined forces to launch the innovative wound healing product Reoxcare across the whole Spanish healthcare system.
The Basque bio-pharmaceutical company Histocell, specialising in regenerative medicine, is the developer and manufacturer of Reoxcare, the antioxidant treatment using natural ingredients for healing chronic wounds, after years of research into oxidative stress.
Histocell produces Reoxcare at its medical manufacturing plant opened in Larrabetzu, Bizkaia in 2018. Through this agreement with Cardiva, a medical marketing company working in the hospital system, Histocell can increase its commercial capacity nationwide.
“This is a very significant agreement for Histocell that strengthens its strategy is a business focusing on the development and manufacturing of innovative product for regenerative medicine. Histocell is taking a chance on partnerships with leading healthcare distribution companies, such as Cardiva, for the marketing of its product Reoxcare,” said Julio Font of Histocell.
Cardiva will distribute Reoxcare in the whole of Spain from its main warehouses located in the business area in Lezama. The company’s Chairman Ignacio Vega stressed that “this agreement highlights Cardiva’s commitment to providing patients with innovative medical solutions to improve their health and remain up to date with the progress being made in the treatment areas where we are involved.”
Thanks to this partnership, the innovative product Reoxcare will be made available in the entire country. So far, it is sold in the Basque Country, Navarra and Galicia, and Osakidetza (Basque Health Service) and Osasunbidea (Navarra Health Service) are currently its main clients.
In 2020 Reoxcare has arrived in 60% of the Basque Healthcare System hospitals, and it is also in use in the Pamplona Healthcare Area, the largest in the region of Navarra. Sales have doubled compared to 2019 and are expected to triple in 2021 thanks to this agreement with Cardiva.
With this agreement, Histocell is continuing to expand its distribution network to different overseas markets such the Netherlands, Italy, Colombia, Chile and Mexico, soon to include China, Singapore, Malaysia and Egypt.